Table 3.
Relationship between Combined FLT3&NPM and the Different Laboratory and Clinical Findings in Adult Acute Myeloid Leukemia Patients
| Combined FLT3&NPM with ITD ratio | p value | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Favourable (n=17) | Unfavorable (n=13) | Intermediate (n=98) | |||||||
| Gender | |||||||||
| Female | 5a (29.4%) | 10b (76.9%) | 49a, b (50.0%) | 0.036 | |||||
| Male | 12a (70.6%) | 3b (23.1%) | 49a, b (50.0%) | ||||||
| Age (years) | |||||||||
| ≤40 | 8 (47.1%) | 9 (69.2%) | 46 (46.9%) | 0.314 | |||||
| >40 | 9 (52.9%) | 4 (30.8%) | 52 (53.1%) | ||||||
| TLC (n=124) | |||||||||
| ≤100 | 13 (76.5%) | 7 (58.3%) | 73 (76.8%) | 0.398 | |||||
| >100 | 4 (23.5%) | 5 (41.7%) | 22 (23.2%) | ||||||
| Hb (n=124) | |||||||||
| ≤10 | 15 (88.2%) | 12 (100.0%) | 83 (87.4%) | 0.541 | |||||
| >10 | 2 (11.8%) | 0 (0.0%) | 129 (12.6%) | ||||||
| PLTs (n=124) | |||||||||
| ≤100 | 14 (82.4%) | 12 (100.0%) | 75 (78.9%) | 0.221 | |||||
| >100 | 3 (17.6%) | 0 (0.0%) | 20 (21.1%) | ||||||
| PB blasts | |||||||||
| ≤ 50 | 3 (17.6%) | 2 (15.4%) | 32 (32.7%) | 0.308 | |||||
| > 50 | 14 (82.4%) | 11 (84.6%) | 66 (67.3%) | ||||||
| BMA blast | |||||||||
| ≤ 50 | 3 (17.6%) | 1 (7.7%) | 16 (16.3%) | 0.835 | |||||
| > 50 | 14 (82.4%) | 12 (92.3%) | 82 (83.7%) | ||||||
| BMA cellularity | |||||||||
| Hypercellular | 16 (94.1%) | 11 (84.6%) | 80 (81.6%) | 0.632 | |||||
| Hypocellular | 1 (5.9%) | 1 (7.7%) | 6 (6.1%) | ||||||
| Normocellular | 0 (0.0%) | 1 (7.7%) | 12 (12.2%) | ||||||
| FAB (n=122) | |||||||||
| M1&M2 | 7 (41.2%) | 7 (53.8%) | 49 (53.3%) | 0.648 | |||||
| M4&M5 | 10 (58.8%) | 6 (46.2%) | 43 (46.7%) | ||||||
| CR (n=90) | |||||||||
| No | 2a (18.2%) | 8b (72.7%) | 35a, b (51.5%) | 0.034 | |||||
| Yes | 9a (81.8%) | 3b (27.3%) | 33a, b (48.5%) | ||||||
| LNS (n=121) | |||||||||
| No | 12 (70.6%) | 7 (58.3%) | 51 (55.4%) | 0.509 | |||||
| Yes | 5 (29.4%) | 5 (41.7%) | 41 (44.6%) | ||||||
| Organomegally (n=121) | |||||||||
| No | 11 (64.7%) | 6 (50.0%) | 57 (62.0%) | 0.689 | |||||
| Yes | 6 (35.3%) | 6 (50.0%) | 35 (38.0%) | ||||||
| CD34 (n=127) | |||||||||
| No | 15a (88.2%) | 5b (38.5%) | 47b (48.5%) | 0.004 | |||||
| Yes | 2a (11.8%) | 8b (61.5%) | 50b (51.5%) | ||||||
| DR (n=127) | |||||||||
| No | 4 (23.5%) | 3 (23.1%) | 32 (33.0% | 0.676 | |||||
| Yes | 13 (76.5%) | 10 (76.9%) | 65 (67.0%) | ||||||
| CD7 (n=127) | |||||||||
| No | 17 (100.0%) | 11 (84.6%) | 78 (80.4%) | 0.135 | |||||
| Yes | 0 (0.0%) | 2 (15.4%) | 19 (19.6%) | ||||||
| Combined FLT3&NPM with ITD ratio | p value | ||||||||
| Favourable (n=17) | Unfavorable (n=13) | Intermediate (n=98) | |||||||
| TKD (n=127) | |||||||||
| Mutant | 1 (5.9%) | 0 (0.0%) | 5 (5.2%) | 1 | |||||
| Wild | 16 (94.1%) | 13 (100.0%) | 92 (94.8%) | ||||||
| DNMTA (n=126) | |||||||||
| Mutant | 2 (12.5%) | 1 (7.7%) | 11 (11.3%) | 1 | |||||
| Wild | 14 (87.5%) | 12 (92.3%) | 86 (88.7%) | ||||||
| IDH1&IDH2 | |||||||||
| Either IDH1 and or IDH2 mutant | 1 (5.9%) | 0 (0.0%) | 9 (9.2%) | 0.847 | |||||
| Both wild | 16 (94.1%) | 13 (100.0%) | 89 (90.8%) | ||||||
| TET2 gene | |||||||||
| mutant TET2 gene | 6a (35.3%) | 3a (23.1%) | 55a (56.1%) | 0.035 | |||||
| wild TET2 gene | 11a (64.7%) | 10a (76.9%) | 43a (43.9%) | ||||||
| BMA cellularity | |||||||||
| Hypercellular | 16 (94.1%) | 11 (84.6%) | 80 (81.6%) | 0.632 | |||||
| Hypocellular | 1 (5.9%) | 1 (7.7%) | 6 (6.1%) | ||||||
| Normocellular | 0 (0.0%) | 1 (7.7%) | 12 (12.2%) | ||||||